The use of recombinant human erythropoietin (r-HuEPO) corrects the anemia of chronic hemodialysis (HD) patients and improves their quality of life. The role of r-HuEPO in the genesis of graft thrombosis is controversial. A retrospective study was conducted of 46 stable chronic HD patients
©1991 American Society of Artificial Internal Organs
